Biomarkers for Metastatic Prostate Cancer
Abstract
In order to identity surface antigens that are differentially expressed in prostate cells during progression from normal to the cancerous and metastatic states, we have sought to use antibody phage display and paired cell lines that differ in tumorigenic and metastatic potential. In this method affinity subtraction and purification selects recombinant monoclonal antibodies binding to antigens that differ between closely related cell types, even without prior knowledge of the nature of the antigens involved. Collaborator Dr. Leland Chung at the Winship Cancer Institute developed lineage-related human prostate cancer cell lines, LNCaP and C4-2, that differ in metastatic potential. Research associates are being trained in a variety of techniques towards this goal. New collaborators Dr. Shafiq Khan and Dr. Sean Kimbro have been involved, and the PI is seeking training in improved methods for isolation of protein affinity reagents. Alterative strategies for identify metastasis-associated biomarkers have been undertaken, including immunochemical screening for know growth factor receptors and responses , as well as differential transcription by microarray-based gene discovery techniques.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2004
- Accession Number
- ADA427158
Entities
People
- Shafiq Khan
Organizations
- Clark Atlanta University